The Identification of a Novel Highly Condensed Pentacyclic Heteroaromatic Ring System 1,3,5,5b,6,8,10,10b‐Octaazacyclopenta[h,i]Aceanthrylene and its Application in the Synthesis of 5,7‐Substituted Pyrazolo[4,3‐d]Pyrimidines

Pyrazolo[4,3‐d]pyrimidines are of interest as potential kinase inhibitors. This article describes the formation of a novel highly conjugated, condensed, centrosymmetric heteroaromatic compound, 4,9‐dichloro‐2,7‐diisopropyl‐1,3,5,5b,6,8,10,10b‐octaazacyclopenta[h,i]aceanthrylene ( 3 ), during the chlorination of 5,7‐dihydroxypyrazolo[4,3‐d]pyrimidine ( 1 ) with phenylphosphonic dichloride. The nucleophilic attack of benzylamine on 3 afforded N‐benzyl‐5‐chloro‐3‐isopropyl‐1H‐pyrazolo[4,3‐d]pyrimidin‐7‐amine ( 6 ), which was further substituted to yield a pyrazolo[4,3‐d]pyrimidine analogue of roscovitine, a well‐known cyclin‐dependent kinase inhibitor.     

氧肟酸类组蛋白去乙酰化酶抑制剂的药效团模型研究

基于24个目前已知的氧肟酸类组蛋白去乙酰化酶抑制剂,我们运用Catalyst软件建立了一个三维药效团模型。其中,最好的药效团模型1,包含了四个化学特征（一个氢键供体,一个芳环和两个疏水基）,相关系数达到0.946,并由另外20个化合物进行了测试验证。我们第一次特征性描述了组蛋白去乙酰化酶的帽子（CAP）部分。我们的研究结果对于设计全新组蛋白去乙酰化酶抑制剂具有很好的指导作用。     

基于支持向量机方法的HERG钾离子通道抑制剂分类模型

对human ether-a-gō-gō related genes(HERG)钾离子通道(钾通道)抑制剂,计算了表征分子组成、电荷分布、拓扑、几何结构及物理化学性质等特征的1559个分子描述符.采用Fischer Score(F-Score)排序过滤和Monte Carlo模拟退火法相结合从中筛选与HERG钾通道抑制剂分类相关的分子描述符.采用支持向量机(SVM)方法,分别以IC50=1.0、10.0μmol·L-1为分类标准,建立了三个分类预测模型.对367个训练集分子,用五重交叉验证.得到正、负样本的平均预测精度分别为84.8%-96.6%、80.7%-97.7%,其总的平均预测精度为87.1%-97.2%,优于其它文献报道结果.对97个外部测试集分子,所建三个模型的总样本预测精度在67.0%-90.1%之间,接近或优于其它文献报道结果.     

流动条件下两种不同亲水基团咪唑啉型缓蚀剂的缓蚀性能

选择了两种含有不同亲水基团的咪唑啉型缓蚀剂, 即1-胺乙基-2-十一烷基咪唑啉(AEI-11)和1-羟乙基-2-十一烷基咪唑啉(HEI-11), 分别在静态及动态条件下,采用失重法、极化曲线法、电化学阻抗谱法研究了上述缓蚀剂对N80钢在CO2饱和的3%(w)NaCl溶液中的缓蚀性能. 研究结果表明, 无论在静态和动态条件下, HEI-11均表现出更佳的缓蚀性能, 即咪唑啉型缓蚀剂的缓蚀性能与亲水基团的极性成正比; 在流动条件为5 m·s-1时, 缓蚀剂的缓蚀效率显著降低. 为了进一步研究缓蚀剂的缓蚀性能与其结构的关系, 运用量子化学法计算了缓蚀剂的EHOMO(最高占有分子轨道)、ELUMO(最低空分子轨道), 结果表明缓蚀剂的缓蚀效率与EHOMO成正比, 与ELUMO及ELUMO与EHOMO的差值驻E成反比.     

人类乙酰胆碱酯酶（ACHE）与抑制剂小分子的对接研究

阿尔茨海默病（Alzheimer’s disease,AD）是一种中枢神经系统致死性神经原发性退行病变,是老年痴呆症中最常见的一种类型．乙酰胆碱酯酶抑制剂（AChEI）是目前治疗AD的主要药物．我们选择他克林、利伐斯的明、石杉碱甲、在研药物TV-3326、多奈哌齐和Anseculin,分别与AChE进行分子对接研究．结果表明：抑制剂与AChE结合能力的大小顺序为：他克林〈利伐斯的明〈石杉碱甲〈TV．3326〈多奈哌齐〈Anseculin,这与实验中测得ACHE1的IC50值反应活性大小一致．上述6类药物分子,Anseculin与AChE的相互作用能力最强．     

Mapping the Active Site of the Bacterial Enzyme LpxC Using Novel Carbohydrate‐Based Hydroxamic Acid Inhibitors*

LpxC (UDP‐3‐O‐(R‐3‐hydroxymyristoyl)‐GlcNAc deacetylase), an enzyme involved in the biosynthesis of lipid A, is crucial for the growth of Gram‐negative bacteria. This enzyme has accordingly been identified as a potential target for the development of novel antibiotics against Gram‐negative bacteria. The carbohydrate‐derived hydroxamic acid 1 (1,5‐anhydro‐2‐C‐(carboxymethyl N‐hydroxyamide)‐2‐deoxy‐3‐O‐myristoyl‐ D‐glucitol) was previously shown to exhibit a wide spectrum of inhibitory activity against LpxC enzymes. Here we describe the preparation of seven analogs of 1 and their enzymatic evaluation. Two of the hydroxyl groups (OH‐3 and 6) of the GlcNAc residue were found to be involved in the binding interaction, and there is an important hydrophobic interaction in the vicinity O‐3 position with the enzyme that recognizes aromatic as well as aliphatic substituents.     

Conduramine F-1 epoxides: synthesis and their glycosidase inhibitory activities

Starting from (±)-7-oxanorbornenone ((±)-14), (±)-(1RS,2RS,3SR,6SR)-6-azidocyclohex-4-en-1,2,3-triol ((±)-24) and (±)-(1RS,2RS,3SR,6RS)-6-azidocyclohex-4-en-1,2,3-triol ((±)-26) were obtained. Epoxidation of the latter cyclohexene derivative gave two epoxides (±)-30 and (±)-31 that were converted into (±)-conduramine F-1 epoxides (±)-10 and (±)-11 and N-substituted derivatives (±)-12 and (±)-13. Compound (±)-(1RS,2SR,3RS,4SR,5RS,6SR)-5-({[4-(trifluoromethyl)phenyl]methyl}amino)-7-oxabicyclo[4.1.0]heptane-2,3,4-triol ((±)-12c) is a good, non-competitive inhibitor of β-xylosidase from Aspergillus niger (K_i=2.2 μM), and (±)-(1RS,2RS,3SR,4RS,5SR,6SR)-5-{[(biphenyl-4-yl)methyl]amino}-7-oxabicyclo[4.1.0]heptane-2,3,4-triol ((±)-13d) is a good inhibitor of α-glucosidase from brewer's yeast (K_i=2.8 μM, non-competitive).     

Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study

A rapid, selective, and sensitive liquid chromatography–tandem mass spectrometry method was developed and validated for the simultaneous determination of unbound sunitinib and its active metabolite N‐desethyl sunitinib in plasma. Plasma and post‐dialysis buffer samples were extracted using a liquid–liquid extraction procedure with acetonitrile–n‐butylchloride (1:4, v/v). Chromatographic separation was achieved on a Waters X‐Terra® MS RP₁₈ column with a mobile phase consisting of acetonitrile and water (60:40, v/v) containing formic acid (0.1%, v/v) using an isocratic run, at a flow‐rate of 0.2 mL/min. Analytes were detected by electrospray tandem mass spectrometry in the selective reaction monitoring mode. Linear calibration curves were generated over the ranges 0.1–100 and 0.02–5 ng/mL for sunitinib and 0.2–200 and 0.04–10 ng/mL for N‐desethyl sunitinib in plasma and in phosphate‐buffered solution, respectively. The values for both within‐day and between‐day precision and accuracy were well within the generally accepted criteria for analytical methods. The analytical range was sufficient to determine the unbound and total concentrations of both analytes. The method was applied for measurement unbound concentrations in addition to total concentrations of sunitinib and its metabolite in plasma of a cancer patient receiving 50 mg daily dose. Copyright © 2012 John Wiley & Sons, Ltd.     

Synthesis of an iminosugar based peptidomimetic analogue

The synthesis of an 1-deoxymannojirimycin based analogue of a known HIV-protease inhibitor is described. The strategies employed for introduction of the pharmacophore groups onto the azasugar scaffold were based on regioselective reactions of the hydroxyl groups of the natural product and of d-fructopyranoside derivatives.     

Synthesis and Crystal Structure of a Novel Ethyl 5-(4-(2-Phenylacetamido)phenyl)-1H-pyrazole-3-carboxylate as an Acrosin Inhibitor

The title compound (ethyl5-(4-(2-phenylacetamido)phenyl)-1H-pyrazole-3-carboxy- late, C20H19N3O3) was synthesized by the reaction of Claisen condensation, cyclization, reduction and acylation. The structure was characterized by X-ray diffraction, MS, NMR and IR. It belongs to the monoclinic system, space group C2/c with a = 22.723(9), b = 9.324(4), c = 18.890(8) , β = 114.259(6)°, V = 3649(3) 3, Dc = 1.272 Mg·m-3, Z = 8, Mr = 349.38, μ = 0.087 mm-1, F(000) = 1472, the final R = 0.0615 and wR = 0.1643. The biological test shows that the title compound has a moderate acrosin inhibition activity.